Company intelligence / Profile preview

Polydex Pharmaceuticals

Toronto, Ontario, Canadadextran.ca ↗

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Polydex Pharmaceuticals was a Canadian-based manufacturer specializing in dextran and its derivatives for both human pharmaceutical and veterinary markets. Its main commercial products were iron dextran (for animal anemia) and dextran sulfate. The company also developed cellulose sulfate gel (“Ushercell”) as an anti-HIV microbicide, which failed in late-stage trials due to lack of efficacy/safety concerns. As of August 2023, the company was acquired by BioSpectra Inc., with all shares purchased for $6.94 million USD.

Therapeutic areas: HematologyPulmonologyInfectious Diseases
Modalities: Small molecule (e.g., dextran derivatives)Polymer-drug conjugate therapy (dextran-based products)Device/gel formulation (cellulose sulfate microbicide gel)
Industry: Biotech

Beyond the preview

Go deeper on Polydex Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polydex Pharmaceuticals.

Explore the full profile